甲状旁腺疾病患者的血小板功能与动脉血栓风险标志物
这项单中心横断面研究纳入40例慢性甲状旁腺功能减退症(HypoPT)、40例原发性甲状旁腺功能亢进症(PHPT)和40名年龄性别匹配的对照,评估氧化应激、内皮功能与血小板活化。HypoPT和PHPT患者氧化应激标志物均较对照升高(P < .001),PHPT患者一氧化氮和血流介导舒张(FMD)降低最明显、颈动脉内膜中层厚度(IMT)增加最明显,血小板聚集在甲状旁腺疾病患者中升高且以PHPT最高。作者认为甲状旁腺激素可能影响血小板反应性,需进一步研究以确定个体化抗血小板治疗的必要性。
要点
- HypoPT和PHPT患者氧化应激标志物均较对照升高(P < .001)。
- PHPT患者一氧化氮和FMD降低最明显、IMT增加最明显。
- 血小板聚集在PHPT最高,HypoPT亦高于对照,PHPT高于HypoPT。
核心结论
- PHPT和HypoPT患者因内皮和血小板功能改变而出现动脉血栓风险标志物升高。
- 作者认为甲状旁腺激素可能影响血小板反应性。
- 作者提出需进一步研究以确定甲状旁腺疾病患者是否需要个体化抗血小板治疗。
研究设计与样本
- 单中心横断面研究,在门诊开展,纳入40例HypoPT、40例PHPT和40名年龄与性别匹配的对照参与者。
- 主要结局指标包括氧化应激、内皮功能和血小板活化标志物的循环水平、钙代谢参数、血流介导舒张(FMD)和颈动脉内膜中层厚度(IMT)。
主要发现
- HypoPT和PHPT患者氧化应激标志物较对照参与者升高(P < .001)。
- PHPT患者一氧化氮降低最明显(P < .001,与HypoPT和对照相比),FMD降低最明显(P < .001和P = .001),IMT增加最明显(P < .001和P = .001)。
- 甲状旁腺疾病患者血小板聚集升高,PHPT患者最高(P < .001,PHPT vs 对照;P = .006,HypoPT vs 对照;P < .001,PHPT vs HypoPT),同时可溶性P选择素和血栓素B2水平升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Both primary hyperparathyroidism (PHPT) and chronic hypoparathyroidism (HypoPT) are associated with the onset and development of cardiovascular diseases (CVDs). However, the molecular mechanisms underlying the effects of parathyroid disorders on endothelial dysfunction and platelet aggregation, two main determinants of CVDs, are not completely understood. OBJECTIVE: This work aimed to evaluate the effects of PHPT and HypoPT on oxidative stress and endothelial and platelet function. METHODS: This monocentric cross-sectional study at an outpatient clinic included 40 individuals with HypoPT, 40 with PHPT, and 40 age- and sex-matched control participants. Main outcome measures included circulating levels of markers of oxidative stress, endothelial function, and platelet activation, calcium metabolism parameters, flow-mediated vasodilation (FMD), and carotid intimal-media thickness (IMT). RESULTS: HypoPT and PHPT patients showed increased oxidative stress markers as compared to control participants (P < .001). Among patients with parathyroid disorders, those with PHPT demonstrated the highest reduction of nitric oxide (P < .001 vs HypoPT and controls) and FMD (P < .001 and P = .001) and a marked increase of IMT (P < .001 and P = .001). We also observed an increased platelet aggregation in patients with parathyroid disorders, with the highest values in PHPT patients (P < .001, PHPT vs controls; P = .006, HypoPT vs controls; P < .001, PHPT vs HypoPT), along with increased levels of soluble P selectin and thromboxane B2. CONCLUSION: PHPT and HypoPT patients have increased markers of atherothrombotic risk due to endothelial and platelet function alterations. Our results suggests that parathyroid hormone may influence platelet reactivity. Further research is needed to determine if personalized antiplatelet therapy is necessary in individuals with parathyroid disorders.
引用
- Naciu AM, Nusca A, Palermo A, et al. Platelet Function and Markers of Atherothrombotic Risk in Individuals With Parathyroid Disorders. J Clin Endocrinol Metab. 2025. PMID: 40037625. doi:10.1210/clinem/dgaf138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。